



### Investment Objective

To achieve consistent and above average capital appreciation over the medium to long-term by investing in companies with market capitalization of not more than RM750 million at the time of acquisition.

### Investor Profile

The fund is suitable for investors who are willing to accept higher level of risk in order to obtain higher growth of their capital and have a medium to long term investment horizon.

### Fund Manager

UOB Asset Management (Malaysia)

### Fund Details


Unit NAV	RM4.3153
Fund Size	RM90.6 million
Inception Date	1 April 2005
Management Fee	1.50% per annum

### Top 10 Holdings

D&O Green Technologies	8.6%
Frontken	8.4%
Dufu Technology	7.7%
Pentamaster	7.3%
Formosa Prosonic	6.8%
Kobay Tech	4.5%
Duopharma Biotech	4.4%
Thong Guan	4.0%
PIE Industrial	3.6%
Able Global	3.5%

Data as at 30 September 2021

### Cumulative Performance Since Inception as at 30 September 2021




### Performance Table as at 30 September 2021

	1 month	3 months	6 months	YTD	1 year	3 years	5 years	Since inception
<b>Fund</b>	2.2%	11.7%	11.2%	17.0%	28.6%	63.3%	94.3%	808.5%
<b>Benchmark</b>	-2.7%	1.4%	-2.6%	-3.8%	4.4%	-9.8%	-3.2%	92.9%

- Benchmark: FTSE Bursa Malaysia Emas Index
- Source: Bloomberg & Gibraltar BSN Life Bhd

Past performance is not indicative of future performance and the performance of the fund is not guaranteed.

### Portfolio Composition as at 30 September 2021



Source: UOBAM



### Manager's Comment

For September 2021, the Fund's NAV/unit increased by 2.2%, outperformed the FBM EMAS which decreased by 2.7% mainly due to the Fund's overweight position in the technology and industrial sectors.

It was largely a negative month for global equities due to the Fed's hawkish direction in the latest FOMC meeting, investors' concern over the US debt ceiling, an uptick in global bond yields and spill-over effects from negative developments in mainland China including the Evergrande debt crisis and power supply outage and its potential impact on global supply chains. The US Fed held benchmark interest rates steady but indicated that the tapering of asset purchases could begin before the year-end.

The FBM KLCI Index closed 4% lower at 1,538 points. Besides weaker global equities, the decline in the local bourse was affected by weakness in glove counters and risk of populist policies after the government's plan to offer a three-month interest waiver on loans for low income borrowers. In another development, the Malaysian government and Pakatan Harapan signed a memorandum of understanding (MOU) on bipartisan cooperation. Towards the end of the month, the government unveiled the 12th Malaysia Plan (2021-2025) with RM400 billion development spending to achieve a targeted average annual GDP growth rate of 4.5%-5.5%.

Going forward, while the concerns on populist policies such as interest waiver and capital gains tax would be negative for market if implemented, we remain positive on the prospects of reopening in Malaysia. With 65% total population already fully vaccinated, most states have also progressed in the National Recovery Plan. In the latest development, interstate travel is now allowed for fully vaccinated individuals.

We would adopt a barbell strategy and target to have a balanced exposure in both growth and value/reopening sectors. For growth exposure, we prefer the technology and industrial sector. As for value/reopening, we focus on consumer and commodities.

#### Disclaimer

This report is for information only and is purely a product summary. Please refer to the product fact sheet available at [www.gibraltarbnsn.com](http://www.gibraltarbnsn.com) for further details. This report shall not be reproduced, copied, circulated or forwarded either in part or otherwise to any persons howsoever without the prior written consent of Gibraltar BSN Life Berhad.

The opinions and information contained herein are based on the latest available data which is believed to be reliable. It is not to be construed as an offer, invitation or solicitation to buy or sell any securities or financial instruments covered by this report. Gibraltar BSN Life Berhad does not warrant the accuracy of anything stated herein in any manner whatsoever and no reliance upon such statement by anyone shall give rise to any claim whatsoever against Gibraltar BSN Life Berhad and/or its associated persons. Gibraltar BSN Life Berhad and/or its associated persons may from time to time have an interest in the securities or financial instruments mentioned by this report. Past Performance of the Funds mentioned in the Report is not an indication of its future performance. Investors/policy holders should rely on their own evaluation to assess the merits and risks of the investment. In considering to invest in an investment-linked fund, investors/policy holders who are in doubt on the action to be taken should consult a professional adviser. Investors/Policy holders have to take note that investments can fluctuate in value and values may fall as well as rise and an investor/policy holder may not get back the amount invested.